Prof Ts Dr Mai Chun Wai from IMU’s Institute for Research, Development and Innovation (IRDI) delivered a keynote address at PASAI 2026 India, highlighting the role of artificial intelligence (AI), synergistic collaboration, and international partnerships in advancing cancer drug discovery, precision medicine, and pharmaceutical innovation.

• IMU IRDI Professor Prof Ts Dr Mai Chun Wai delivered a keynote address at PASAI 2026 India
• Conference focused on AI, pharmaceutical sciences, and IPR strategies
• PASAI 2026 brought together global researchers, industry leaders, and policymakers

April 2026 will stand out as a pivotal moment, where pharmaceutical sciences, artificial intelligence (AI), and intellectual property rights (IPR) converged to advance pharmaceutical care.

This convergence took center stage at the two-day International Conference on “Pharma and Allied Sciences in the Age of AI: Innovations and Intellectual Property Right (IPR) Strategies (PASAI-2026)” in India, hosted by the School of Medical & Allied Sciences (SMAS), KR Mangalam University (KRMU). More than a dialogue platform, the conference brought together professionals united by a mission to revolutionise treatment.

As an IMU Institute for Research, Development and Innovation (IRDI) Professor, Prof Ts Dr Mai Chun Wai was honored to deliver a keynote address. He advocated for synergism in cancer drug design and called on attendees—leaders, researchers, and innovators—to embrace collaboration, emphasizing that collective effort drives life-changing breakthroughs.

This advocacy aligns with IMU’s commitment to prioritise precision health by investing in state-of-the-art labs and interdisciplinary teams, focusing on targeted anti-cancer solution.

The KRMU organising committee curated a diverse cohort of global professionals—renowned researchers, academicians, industry leaders, policy experts, and young minds—united by a goal:

• Unlocking AI’s transformative potential in pharma
• Building robust IPR strategies, and
• Reimagining cancer drug design through synergism

April 2026 will stand out as a pivotal moment, where pharmaceutical sciences, artificial intelligence (AI), and intellectual property rights (IPR) converged to advance pharmaceutical care.

This convergence took center stage at the two-day International Conference on “Pharma and Allied Sciences in the Age of AI: Innovations and Intellectual Property Right (IPR) Strategies (PASAI-2026)” in India, hosted by the School of Medical & Allied Sciences (SMAS), KR Mangalam University (KRMU). More than a dialogue platform, the conference brought together professionals united by a mission to revolutionise treatment.

As an IMU Institute for Research, Development and Innovation (IRDI) Professor, Prof Ts Dr Mai Chun Wai was honored to deliver a keynote address. He advocated for synergism in cancer drug design and called on attendees—leaders, researchers, and innovators—to embrace collaboration, emphasizing that collective effort drives life-changing breakthroughs.

This advocacy aligns with IMU’s commitment to prioritise precision health by investing in state-of-the-art labs and interdisciplinary teams, focusing on targeted anti-cancer solution.

The KRMU organising committee curated a diverse cohort of global professionals—renowned researchers, academicians, industry leaders, policy experts, and young minds—united by a goal:

• Unlocking AI’s transformative potential in pharma
• Building robust IPR strategies, and
• Reimagining cancer drug design through synergism

Prof Mai’s keynote focused on the intersection of AI and cancer drug discovery. He highlighted AI’s role in revolutionising the pharmaceutical pipeline—from identifying cancer targets and designing precision molecules to streamline clinical trials and ensuring post-market safety—while stressing that AI alone is insufficient.

Synergism is the key! Prof Mai emphasized strategic collaboration between AI experts and cancer researchers, academia, industry, and policymakers is critical to ensure an impactful research outcome.

Beyond cell-targeted research, IRDI actively champions international collaboration by forging partnerships with global institutions, researchers, and industry players to amplify impact. Through cross-border knowledge exchange, joint research initiatives, and collaborative clinical trials, IMU aims to transform local cell-targeted therapy innovations into solutions with global relevance.

Prof Ts Dr Mai Chun Wai noted that partnerships—both at the conference and beyond—translate promising ideas into life-saving drugs. He added that strong IPR frameworks empower continued collaboration and innovation, prioritising patients’ needs.

The subsequent Q&A session highlighted the power of collective action, embodying the synergism IMU champions.

Gratitude is extended to KRMU’s organizing team for their tireless work in delivering this world-class event.

Support from organisations underscores the importance of collaboration in advancing pharmaceutical research. The supporting organisations include:

• The Council for Scientific and Industrial Research (CSIR) India,
• Department Of Scientific and Industrial Research (Dsir),
• Anusandhan National Research Foundation (ANRF),
• Haryana Department of Science and Technology (Haryana DST), and
• Haryana State Council for Science and Technology (HSCST)

Prof Ts Dr Mai Chun Wai thanked the organising committee for trusting him with the keynote, providing a platform to

• Share his passion for synergism and
• Highlight IMU’s commitment.

The experience allowed him to learn from industry leaders, reaffirming IMU’s mission to lead in cell-targeted research and international collaboration.

IMU is strengthening its cell-targeted research while expanding global partnerships through

• Joint projects,
• Student and faculty exchanges, and
• Shared access to cutting-edge technologies.

Together, these efforts are helping to build a global community focused on transforming cancer care.

Prof Ts Dr Mai Chun Wai believes synergism is humanity’s greatest strength, and with IMU at the forefront, breakthroughs are possible. He urged attendees to carry forward PASAI-2026’s spirit: collaborate fiercely, innovate boldly, and embrace synergism.

Together, with institutions like IMU leading research and collaboration, they can design better drugs and a brighter future for cancer patients.